ACR-ACNM-ASTRO-SNMMI Practice Parameter for the Performance of Therapy With Radium-223.

Area of Science:

• Oncology
• Radiopharmaceutical Therapy
• Medical Physics

Background:

• Unsealed radiopharmaceutical sources aim for cure or prolonged survival, symptom reduction, and minimized side effects.
• Radium-223 dichloride is an alpha particle-emitting isotope utilized in targeted bone therapy.
• Effective radiopharmaceutical therapy necessitates collaboration between clinical management and therapy administration teams.

Purpose of the Study:

• To provide a practice parameter for physicians administering radium-223 therapy.
• To guide safe and effective clinical use of radium-223 based on current knowledge.
• To ensure compliance with applicable regulations for radiopharmaceutical therapy.

Main Methods:

• Developed by the ACR Committee on Practice Parameters in collaboration with ACNM, ASTRO, and SNMMI.
• Followed the established ACR process for developing practice parameters and technical standards.
• Approved by all contributing professional societies.

Main Results:

• The practice parameter addresses key factors for appropriate, safe, and effective radium-223 use.
• Topics include personnel qualifications, treatment specifications, documentation, and radiation safety.
• Quality control, infection control, and patient education are also covered.

Conclusions:

• This parameter serves as a guide for clinical radium-223 use.
• Facilitates safe and effective medical care aligned with patient needs and current knowledge.
• Aims to assist practitioners in achieving optimal therapeutic goals.